Regeneron and Bayer's efforts to defend their lucrative eye disease therapy Eylea from competition have been boosted by FDA approval of a new high-dose formulation of the drug. The US regulator ...

Two one-shot doses of 4D-150 are being tested in the study and compared to Eylea. The high dose of the gene therapy – which is designed to express both aflibercept and an RNA interference (RNAi ...

Despite lackluster sales of Eylea’s high-dose formulation and Sanofi-partnered Dupixent, Regeneron beat Q4 forecasts overall ...

“Impressively, the latest three-year EYLEA HD results show a substantial portion of patients were able to sustain visual and anatomic benefits with only two doses a year. This adds yet another ...

Eylea high dose adoptions are still limited at this stage, and with the backdrop of branded and biosimilar competition, UBS does not expect an inflection in the near-term., the analyst tells ...

Brokerage slashed price target to $738 from $1130. The brokerage highlighted limited adoption of high-dose Eylea amid rising branded and biosimilar competition. UBS projects a 14% drop in Eylea ...

Regeneron Pharmaceuticals has announced results from the phase 3 QUASAR trial and its extension study of the phase 3 PULSAR ...

Furthermore, in patients treated with EYLEA HD through 36 weeks, 88% of patients were able to sustain an 8-week dosing regimen following 3 initial monthly doses, and 93% of patients maintained an ...

Regular dose Eylea sales in the US were $1.2 billion, or an 11% year-on-year decline, while Eylea high-dose sales in the US were $305 million, or 148% year-on-year growth. Although Roche’s ...

Regeneron Pharmaceuticals Inc. (REGN) announced encouraging outcomes from the Phase 3 QUASAR trial, which evaluated the efficacy of ...